Navigation Links
Watson Confirms Pataday™ Patent Challenge
Date:6/14/2011

PARSIPPANY, N.J., June 14, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%.  Watson's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is a generic version of Alcon, Inc.'s Pataday™ (olopatadine hydrochloride ophthalmic solution) 0.2%, which is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Alcon Research, Ltd., Alcon Pharmaceuticals, Ltd., and Kyowa Hakko Kirin Co., Ltd. filed suit against Watson on June 9, 2011 in the United States District Court for the Southern District of Indiana seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent Nos. 5,641,805, 6,995,186, and 7,402,609.  Alcon's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until October 29, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending April 30, 2011, Pataday had total U.S. sales of approximately $224 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, 2015 ... 47.54 billion by 2020, according to a new study by Grand ... II diabetes and the presence of high unmet needs in emerging ... China are expected to be two of the most ... lifestyle induced diseases such as obesity and growing global geriatric population ...
(Date:6/29/2015)... CITY, Mo. , June 29, 2015  Missouri ... the 2015 first quarter data from the state,s real-time, ... (NPLEx). States across the United ... Missouri one of 31 across the country ... attempted pseudoephedrine (PSE) purchases at the point of sale.  ...
(Date:6/29/2015)... KING OF PRUSSIA, Pa. , June 29, 2015 ... Alsharabati, MD, University of Alabama at Birmingham, ... 2015 Interlaken Leadership Award for ... global awards program provides monetary grants and/or product supply ... potential role of immunoglobulin (Ig) therapy in the treatment ...
Breaking Medicine Technology:Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 2Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 3Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 4CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 2CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 3
... 5, 2011 In its April issue, published this ... magazine has announced the winners of the fourteenth annual ... (Logo:  https://photos.prnewswire.com/prnh/20101214/LA16070LOGO) Sponsored by MD+DI ... the premier awards program for the medical technology community. ...
... April 5, 2011 RESMED INC. (NYSE: RMD ... will release its results for the third quarter and nine ... press release with ResMed,s results will be issued after 1:00 ... call and webcast to review its results, market trends, and ...
Cached Medicine Technology:37 Innovative Products Win Medical Design Excellence Awards 237 Innovative Products Win Medical Design Excellence Awards 337 Innovative Products Win Medical Design Excellence Awards 4ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2
(Date:6/29/2015)... , ... June 30, 2015 , ... ... set of revised Guidelines for Neuro Musculoskeletal Thermography and Sympathetic Skin Response Studies.* ... Guidelines that were first published in 2006, are intended to aid physicians and ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one of ... John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians and ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons of ...
(Date:6/29/2015)... ... , ... Mediaplanet has released the first edition of “Heart ... glossy, full-color special section hit newsstands Friday, June 26th, and was distributed within ... with an estimated readership of 1.3 million. The digital component is being distributed ...
(Date:6/29/2015)... YORK, NEW YORK (PRWEB) , ... June 29, ... ... sleep apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The ... Drug Administration and is an alternative to continuous positive airway pressure (CPAP), the ...
(Date:6/29/2015)... ... June 29, 2015 , ... National HealthCare Associates ... customer service for the 40-center nursing home group. Sixteen of their centers were ... the United States in one or more customer service areas. Those centers received ...
Breaking Medicine News(10 mins):Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 2Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4
... Foundation site trends indicating measles risk remains highWASHINGTON, ... states - California, Pennsylvania, Maryland and Iowa - ... children living in the United States as well ... of the disease.(Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ...
... disease, experts say , , FRIDAY, April 17 (HealthDay News) -- ... (PTU) in children has been endorsed by the Endocrine Society. ... 9 New England Journal of Medicine , two experts ... and should no longer be used as a first-line treatment ...
... The following statement may be attributed to Amy ... Research: "We are pleased that the National Institutes of ... of creating federal guidelines to remove restrictions on embryonic ... great promise, today,s draft guidelines that would allow federal ...
... makes prevention more difficult, study finds, , , FRIDAY, April ... commit suicide have been diagnosed with a mental disorder. ... death certificates list mental disorder as a contributing factor, ... it more difficult for health-care policymakers to create prevention ...
... the United States Great Depression of 1929 has the ... and well-being across the parameters of occupational, spiritual, emotional, ... pace, people are at risk for suffering lowered self ... Miami,s St. Thomas University Counseling Programs - ...
... Offers SolutionMURFREESBORO, Tenn., April 17 Medication mistakes at ... to a recent national study, and the need for ... to Shane Reeves, D. Pharm and co-owner of Reeves-Sain.Reeves ... system of bottles to a clearer, more easily managed ...
Cached Medicine News:Health News:U.S. Measles Outbreaks Highlight Global Need 2Health News:Drug May Be Dangerous for Kids With Graves' Disease 2Health News:Death Certificates Incomplete for Suicide Victims 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Medication Mismanagement Is a Growing Danger 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: